Hospitales Parque redoubles its technological commitment with two new investments. The group, integrated into the diversification area of the Caser insurance company, has undertaken an investment of $1.53 million (€1.3 million) in technological equipment for image diagnosis in two of its hospitals, in Tenerife and in Badajoz, as advanced by the company.
The first of the investments is the one of the Hospital Parque Vegas Altas, in Don Benito (Badajoz). This facility takes a new qualitative leap in its diagnostic services, as it has acquired and put into service the Philips Ingenia 1.5T Omega 70-centimeter Gantry magnetic resonance imaging.
The new diagnostic imaging equipment constitutes, up to now, the most modern resonance in Extremadura and has meant an investment of $940,000 (€800,000), as confirmed by Hospitales Parque.
Read more about the latest investment in technology by the Hospital Parque and find the latest business news in the world with the Born2Invest mobile app.
Hospitales Parque entrusted Philips with the commissioning and service of these two equipments
The advanced clinical software that the resonance guarantees “the realization of all kinds of complex studies […], which allow studies with free breathing and advanced studies of perfusion and diffusion,” explained from the group.
Likewise, it performs dynamic studies for breast and prostate for early detection of cancer, which allows avoiding biopsies if the resonance is negative or directing the biopsy to the prostate area if the tumor is found on MRI. In addition, studies of claustrophobic and pediatric patients requiring sedation are also carried out in collaboration with the anesthesiology service of the Extremadura hospital.
The operator has also spent more than $580,000 (€500,000) at its Hospital Parque Tenerife to set up a computerized axial tomography (CT) machine. This technology allows progress in the early diagnosis of some of the most frequent cancers, such as lung cancer, or access to the origin of the coronary arteries.
The group’s turnover exceeded $47 million (€40 million) in 2019
As in Don Benito, the new device in Tenerife is of the Philips brand. This has 128 virtual cuts of the area analyzed, to which other technical parameters of the last generation are added. This makes it possible to obtain a high-quality three-dimensional image in less time as a result of greater speed in taking the captures.
Another advantage of the new scanner is the application of minimum radiation dose, 80% less than in the case of conventional devices. This aspect, together with the reduction of exposure time, makes it “a first-rate tool for the early diagnosis of certain diseases,” the group pointed out. Hospitales Parque reached a turnover of $55.8 million (€47.5 million) in 2019, which meant a growth of more than 70% compared to the previous year.
Among its latest movements, the integration of the Laserclinic medical center of Manacor (Mallorca) into its network stands out. The management depends directly on the Hospital de Llevant, a center dependent on the group. The polyclinic center in Manacor occupies an area of 1,400 square meters.
Laserclinic, with more than ten years of service, offers the specialties of dermatology, otolaryngology, pain clinic, general surgery, digestive system, podiatry, urology, cardiology, general medicine, endocrinology, aesthetic medicine, nutrition and dietetics, psychology, pediatrics and physiotherapy. After the agreement reached with Laserclinic, Hospitales Parque will now manage an activity that in 2019 will involve a total of more than 17,000 medical acts and 14,000 physiotherapy sessions.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
Sono Motors introduces community advisory board
Sono Motors unveiled the latest prototype of its electric minivan with solar cells in the body. In parallel with the...
Ysios Capital invests 30 million in 2020 and plans to enter four companies in 2021
In a year marked by the COVID-19 pandemic, the venture capital manager Ysios Capital carried out six follow-on operations and...
Oxxo enters the fintech ecosystem with its digital wallet Spin
On March 2nd, Oxxo presented Spin, a digital wallet through which it will be possible to manage, send and receive...
AEDESEO asks for €57,000 in crowdfunding to research a new treatment
AEDESO wants to start a clinical study and launched a crowdfunding campaign to raise the necessary money for it. Patients...
Mainz-based biotech company ActiTrexx receives €3.5 million in financing
The biotech company ActiTrexx has recently closed a Series A financing round, during which it raised $4.2 million (€3.5 million)....
Biotech7 days ago
VB Devices closes a €1.1 million round to consolidate its market entry
Cannabis6 days ago
Legalization trend drives cannabis ETFs to significantly grow
Featured7 days ago
ARisk, the startup of predictive risk algorithms, closes €350,000 round
Crypto7 days ago
Bitcoin whale alert: major investors dump large amounts of BTC